Consensus Ocugen, Inc.

Equities

OCGN

US67577C1053

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:30:00 17/01/2026 am IST			5-day change	1st Jan Change
1.690 ^USD	+4.32%		+12.67%	+25.19%

06/11	Ocugen, Inc., Q3 2025 Earnings Call, Nov 05, 2025
05/11	Ocugen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

Evolution of the Average Target: Ocugen, Inc.

Evolution of the Target Price: Ocugen, Inc.

Changes in Analyst Recommendations: Ocugen, Inc.

a5defebed81.ajuO6fTcEUNeT4HxIQQ0NGkM5Fevk3Vc6Ic5_SXLing.CXPAq8yVYS9tBc3CdU9MbVtgjjb-ph8ovO1blBSfsjQIY7iKmeg8Fzp3tQ~8bb12b44e3ccabbb224a9932b5cec192

Analysts' recommendations: Ocugen, Inc.

06/25/06	Chardan Capital Adjusts Ocugen Price Target to $7 From $6, Maintains Buy Rating	MT
22/24/22	Chardan Adjusts Price Target on Ocugen to $5 From $4, Maintains Buy Rating	MT
22/24/22	Chardan Raises Price Target on Ocugen to $5 From $4, Keeps Buy Rating	MT
24/24/24	HC Wainwright Adjusts Price Target on Ocugen to $7 From $5, Maintains Buy Rating	MT
31/23/31	Cantor Fitzgerald Adjusts Ocugen's Price Target to $2 From $2.50, Keeps Overweight Rating	MT
08/23/08	Chardan Research Raises Ocugen's Price Target to $4 From $3.50, Buy Rating Kept	MT
01/23/01	Chardan Upgrades Ocugen to Buy From Neutral, Citing Recent Sell-Off	MT
01/23/01	Mizuho Adjusts Price Target on Ocugen to $3 From $5, Maintains Buy Rating	MT
23/22/23	Mizuho Securities Starts Ocugen at Buy With $5 Price Target	MT
15/22/15	HC Wainwright Adjusts Ocugen's Price Target to $6 from $7, Maintains Buy Rating	MT
15/22/15	Roth Capital Reinstates Ocugen at Buy with $8 Price Target	MT
02/22/02	Cantor Fitzgerald Starts Ocugen at Overweight With $4.50 Price Target	MT
09/22/09	Chardan Trims Ocugen's Price Targe to $3.50 From $4, Maintains Neutral Rating	MT
09/22/09	Chardan Research Adjusts Ocugen's Price Target to $3.50 From $4, Maintains Neutral Rating	MT
28/22/28	HC Wainwright Adjusts Ocugen's Price Target to $8 from $10, Maintains Buy Rating	MT
14/21/14	Analyst recommendations: Alliant Energy, Ally Financial, Alphabet, HSBC, Honest...
11/21/11	OCUGEN : Chardan Adjusts Ocugen PT to $4.50 From $8, Maintains Neutral Rating	MT
11/21/11	OCUGEN : Cantor Fitzgerald Adjusts Ocugen PT to $4 From $11, Maintains Neutral Rating	MT
11/21/11	OCUGEN : HC Wainwright Adjusts Ocugen's Price Target to $10 From $12, Maintains Buy Rating	MT
11/21/11	OCUGEN : Roth Capital Cuts Ocugen to Neutral From Buy, Price Target to $6 From $10	MT
10/21/10	OCUGEN : Chardan Adjusts Price Target on Ocugen to $8 From $13, Maintains Neutral Rating	MT
10/21/10	Today's analyst recommendations: Oracle, Facebook, Berkeley, Acushnet, Ocugen, London Stock Exchange, Flutter...
07/21/07	OCUGEN : Cantor Fitzgerald Downgrades Ocugen to Neutral From Overweight, Adjusts PT to $11 From $15	MT
03/21/03	OCUGEN : Cantor Fitzgerald Adjusts Ocugen PT to $15 From $4, Maintains Overweight Rating	MT
09/21/09	OCUGEN : Chardan Capital Downgrades Ocugen to Neutral From Buy on Valuation, Adjusts Price Target to $13 From $0.70	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	OCUGEN, INC.					+432.54%
	LONZA GROUP AG					+21.2%
	IQVIA HOLDINGS INC.					+9.24%
	BEONE MEDICINES AG					+19.52%
	CELLTRION, INC.					+12.8%
	REVOLUTION MEDICINES, INC.					-24.34%
	MEDPACE HOLDINGS, INC.					-10.66%
	Average					+65.76%
	Weighted average by Cap.					+10.15%